Literature DB >> 16555997

Cytochrome P450 1B1: a novel anticancer therapeutic target.

Morag C E McFadyen1, Graeme I Murray.   

Abstract

Cytochrome P450 (CYP)1B1 is overexpressed in tumor cells and is also recognized as a biomarker of the tumor phenotype. This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target. The range of therapeutic strategies including immunotherapeutics, CYP1B1-activated prodrugs and CYP1B1 inhibitors, that are currently being developed to exploit the presence and activity of CYP1B1 in tumor cells is outlined. The therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a Phase I clinical trial.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16555997     DOI： 10.1517/14796694.1.2.259

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  22 in total

Review 1.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Authors:  Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

2.  CYP1B1 deficiency ameliorates obesity and glucose intolerance induced by high fat diet in adult C57BL/6J mice.

Authors:  Xiaocong Liu; Tingting Huang; Lu Li; Yumeng Tang; Yatao Tian; Suqing Wang; Cuifang Fan
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

3.  The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene.

Authors:  Tracey Einem Lindeman; Miriam C Poirier; Rao L Divi
Journal:  Mutagenesis       Date:  2011-06-13       Impact factor: 3.000

4.  Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents.

Authors:  Jinyun Dong; Guang Huang; Qijing Zhang; Zengtao Wang; Jiahua Cui; Yan Wu; Qingqing Meng; Shaoshun Li
Journal:  Medchemcomm       Date:  2019-07-02       Impact factor: 3.597

Review 5.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

Review 6.  The emerging role of microRNAs in drug responses.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Opin Mol Ther       Date:  2010-12

7.  miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.

Authors:  Wenjing Mu; Chaobo Hu; Haibin Zhang; Zengqiang Qu; Jin Cen; Zhixin Qiu; Chao Li; Haozhen Ren; Yixue Li; Xianghuo He; Xiaolei Shi; Lijian Hui
Journal:  Cell Res       Date:  2015-02-20       Impact factor: 25.617

8.  A suite of activity-based probes for human cytochrome P450 enzymes.

Authors:  Aaron T Wright; Joongyu D Song; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2009-08-05       Impact factor: 15.419

9.  Transcriptomic Profiling of 3D Glioblastoma Tumoroids for the Identification of Mechanisms Involved in Anticancer Drug Resistance.

Authors:  Nipha Chaicharoenaudomrung; Phongsakorn Kunhorm; Wilasinee Promjantuek; Narawadee Rujanapun; Nudjanad Heebkaew; Natchadaporn Soraksa; Parinya Noisa
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

10.  Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model.

Authors:  Yue-Fang Liu; Bin-Shan Zha; Hui-Lin Zhang; Xiao-Jing Zhu; Yu-Hua Li; Jin Zhu; Xiao-Hong Guan; Zhen-Qing Feng; Jian-Ping Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.